All patients in ProTrans-Repeat are now treated

Booking.com

NextCell Pharma AB (“NextCell”) announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed.
NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated

Source: All patients in ProTrans-Repeat are now treated

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.